SLC18A2 and Alzheimer disease: Our observed loss of a glycosylated form of VMAT2 with a diagnosis of AD corroborates the loss of VMAT2 observed in AD (Lehericy et al., 1994) as well as the loss of the 72 kDa glycosylated form of VMAT2 from the vesicle-enriched synaptic fraction of the aging rat brain (Cruz-Muros et al., 2008).